Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05883137

High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill

Intubation in the intensive care unit is a standard procedure with a high risk of adverse events such as hypoxaemia and cardiovascular instability. However, it is demonstrated that HFNO (High Flow Nasal Oxygen) for pre and perioxygenation is feasible and, in many situations, prolongs the safe apnoeic period after anaesthesia induction. Previous data of the use of HFNO during intubation of the critically ill is conflicting.

With the new device Optiflow Switch, which allow its combination with NIV or tight facemask with perioxygenation, we aim to evaluate whether this could reduce intubation-related hypoxaemia and other adverse events.

The general purpose of this project is to compare the addition of Optiflow Switch for pre- and perioxygenation to traditional preoxygenation using a tight-fitting mask or NIV during intubation in adult intensive care patients in a prospective before-and-after study design.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Karolinska University Hospital

Stockholm, Stockholm County, 17176, Sweden

Location status: Recruiting

Location contact

Ida-Maria Forsberg, PhD

CONTACT

[email protected]

+46704381445

About this study

This study aims to investigate whether apnoeic oxygenation with Optiflow Switch during tracheal intubation of the critically ill may prevent severe hypoxaemic events. Critically ill patients requiring intubation in the intensive care unit will be preoxygenated with tight facemask/NIV and Optiflow Switch or only tight facemask/ NIV.

During a period of 6-12 months with an aim to include a minimum of 50 patients, patients will be preoxygenated according to routine practice, 100% oxygen via a tight-fitting mask or NIV. During the following 6-12 months, we will change the clinical routine to adding HFNO with Optiflow Switch. During this time, patients, without contraindications will be pre and perioxygenated with HFNO, Optiflow Switch 40-70 L/min, 100 % O2, in combination with a tight facemask or NIV.

Before preoxygenation, the need for and methods for oxygen delivery is noted. Baseline patient characteristics (age, BMI, comorbidities, smoking history, airway related data) and the reason for intensive care admission and intubation will be registered. Scores for physiological compromise and length of intensive care prior to intubation will be noted.

In both groups, the duration of preoxygenation and drugs for anaesthesia induction are chosen by the intensive care physician responsible. Blood gas analysis for arterial oxygen and carbon dioxide partial pressure will be analysed before and after intubation. Before, during and after intubation, vital parameters will be registered.

Intubation-related data and immediate complications such as arterial hypotension, severe cardiac arrhythmia, cardiac arrest, death, oesophageal intubation, regurgitation, or a need for a surgical airway will be noted. Later complications such as ventilator-associated pneumonia and mortality at day 28 as well as duration of mechanical ventilation, length of stay in ICU will be registered.

Patients with contraindications against HFNO and if the responsible anaesthetist is not comfortable using HFNO will be preoxygenated with a traditional facemask or NIV and included in the study group of traditional preoxygenation.

Data will also be collected from the intensive care patient chart regarding all intubations during the study period in order to find patients not included in the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult, ≥18 years old
  • Intensive care patients that require tracheal intubation for any indication

Exclusion criteria

  • Patients with skull or facial injuries where the application of nasal cannula is to be avoided, decided by the intensivist.
  • Pregnancy
  • Total nasal obstruction
  • Deemed not suitable for any other reason than the aforementioned

Treatment and study plan

Optiflow Switch

Device

High flow nasal oxygen with the Optiflow Switch device

Primary outcomes

  1. Desaturation up until 5 minutes after intubation

    Time frame: 5 minutes post intubation

    Desaturation (below 90% SpO2 or >5 % if <90% after preoxygenation) up until 5 minutes after intubation in patients receiving standard preoxygenation or with the addition of perioxygenation with HFNO.

Secondary outcomes

  1. Frequency of complications

    Time frame: 5 minutes

    Difference of frequency of complications (severe arrhythmias or hypotension, cardiac arrest, death) when using Optiflow Switch peri-oxygenation compared to traditional preoxygenation.

  2. Change of intubation method

    Time frame: 5 minutes

    Difference in change of intubation method when using Optiflow Switch peri-oxygenation compared to traditional preoxygenation.

  3. Intensive care length of stay

    Time frame: 30 days

    Difference in long-time intensive care outcome (length of stay, 30-day mortality, ventilator-induced pneumonia) when using Optiflow Switch peri-oxygenation compared to traditional preoxygenation.

  4. ETCO2 in the first breath after intubation

    Time frame: 5 minutes

    Difference in ETCO2 in the first breath after intubation when using Optiflow Switch peri-oxygenation compared to traditional preoxygenation.

  5. Duration of intubation

    Time frame: 5 minutes

    Difference in duration of intubation (from the start of laryngoscopy until ETCO2 is registered) when using Optiflow Switch peri-oxygenation compared to traditional preoxygenation.

  6. Arterial oxygen and carbon dioxide levels after intubation

    Time frame: 30 minutes

    Difference in arterial oxygen and carbon dioxide levels after intubation when using Optiflow Switch peri-oxygenation compared to traditional preoxygenation.

  7. Perceived intubation difficulties

    Time frame: 30 minutes

    Difference in graded (scale 1-5) perceived difficulty during intubation when using Optiflow Switch peri-oxygenation compared to traditional preoxygenation.

  8. Number of intubation attempts

    Time frame: 30 minutes

    Difference in number of intubation attempts when using Optiflow Switch peri-oxygenation compared to traditional preoxygenation.

  9. Number of oesophageal intubations

    Time frame: 30 minutes

    Difference in number of oesophageal intubations when using Optiflow Switch peri-oxygenation compared to traditional preoxygenation.

  10. 30-day mortality

    Time frame: 30 days

    Difference in 30-day mortality when using Optiflow Switch peri-oxygenation compared to traditional preoxygenation.

  11. Perceived operator stress

    Time frame: 30 minutes

    Difference in perceived operator stress during intubation when using Optiflow Switch peri-oxygenation compared to traditional preoxygenation.

Study contacts

Contact information is provided by the study sponsor or research team.

Ida-Maria Forsberg, PhD

CONTACT

[email protected]

+ 46704381445

Sponsors and collaborators

Lead sponsor

Region Stockholm

Other Gov

Collaborators

  • Karolinska Institutet

Registry information

Official study title

High-flow Nasal Oxygenation for Apnoeic Oxygenation With Optiflow Switch During Intubation of the Critically Ill Adult- a Prospective Before-and-after Study

Acronym: HiPOXIC

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
May 31, 2023
Registry last updated
Apr 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.